赛莱乐与川芎嗪治疗急性脑梗死的对照研究  

A COMPARATIVE STUDY WITH BUFLOMEDIL VS LIGUSTRAZINI IN TREATING ACUTE CEREBRAL INFARCTION

作　　者：穆军山[1] 杨渤生[1] 洪一飞[1] 殷红兵[1] 叶建新[1] 倪铭孔[1] 林航[1] 林敏[1] 

机构地区：[1]解放军福州总医院神经内科,350025

出　　处：《中国现代医学杂志》2001年第3期47-48,共2页China Journal of Modern Medicine

摘　　要：目的 :研究新型具有多重药理作用的血管活性药物———赛莱乐治疗急性脑梗死的对照研究。方法 :33例急性脑梗死患者给予赛莱乐静滴治疗 14d ,并设对照组。分别观察治疗前后脑卒中患者临床神经功能缺损程度评分 ,并测定血液流变学。结果 :赛莱乐的总有效率和显效率分别为 90 .9%和 75 .8% ,明显优于对照组的74.2 % ,5 4.8% (P <0 .0 5 )。结论 :赛莱乐能改善缺血性脑组织的血供 ,能抑制血栓形成 ,防止梗死灶进一步发展 ,疗效显著 。Objective:To study the therapeutic effects of buflomedil—— a new vasomotor of several kinds of pharmacological effects in treating acute cerebral infarction.Methods:Thirty-three patients with acuted cerebral infarction treated with buflomedil through intravenous drip for 14 days,and the compared group was establisthed.The changes in total score of neurological functional damage were observed and the hemorheology was surveyed in the patients before and after treatment.Results:The total clinical effective rate and the remarkable effective rate in patients treated with buflomedil(90.9%,75.8%,respectively) were greater than those of control(74.2%,54.8%,respectively)(P<0.05).Conclusions:Buflomedil is a safe and effective drug in treating patients with acute cerebral infarction.

关 键 词：赛莱乐 脑梗死 血液流变学 药物评价 治疗 

分 类 号：R743.330.5[医药卫生—神经病学与精神病学]